



Review

Extracorporeal blood purification in burns: A review



Katharina Linden^{a,*}, Ian J. Stewart^b, Stefan F.X. Kreyer^a,
Vittorio Scaravilli^a, Jeremy W. Cannon^{b,c}, Leopoldo C. Cancio^{a,d},
Andriy I. Batchinsky^a, Kevin K. Chung^{a,c}

^a U.S. Army Institute of Surgical Research, Fort Sam Houston, San Antonio, TX 78234, United States

^b San Antonio Military Medical Center, Fort Sam Houston, San Antonio, TX 78234, United States

^c Uniformed Services University of the Health Sciences, Bethesda, MD, 20814, United States

^d University of Texas Health Science Center, San Antonio, TX 78229, United States

ARTICLE INFO

Article history:

Accepted 20 January 2014

Keywords:

Thermal injury

Blood purification

Cytokine removal

Burns

ABSTRACT

A prolonged and fulminant inflammatory state, with high levels of pro and anti inflammatory mediators, is seen after extensive thermal injury. Blood purification techniques including plasma exchange, continuous venovenous hemofiltration, and adsorbing membranes have the potential to modulate this response, thereby improving outcomes. This article describes the scientific rationale behind blood purification in burns and offers a review of literature regarding its potential application in this patient cohort.

© 2014 Elsevier Ltd and ISBI. All rights reserved.

Contents

1. Introduction	1072
2. Rationale for blood purification	1072
3. Pathophysiology of burns and why blood purification makes sense	1072
4. Blood purification techniques in burns	1073
4.1. Plasma exchange	1073
4.2. Continuous venovenous hemofiltration (CVVH)	1073
5. Emerging blood purification techniques	1074
5.1. Adsorptive membranes and columns	1074
5.1.1. Polymyxin B columns	1074
5.1.2. PMMA membranes	1074
5.1.3. Cytokine adsorbing columns	1074

* Corresponding author. Tel.: +1 210 539 8730.

E mail address: Katharina.Linden@ukb.uni-bonn.de (K. Linden).

<http://dx.doi.org/10.1016/j.burns.2014.01.013>

0305 4179/© 2014 Elsevier Ltd and ISBI. All rights reserved.

Report Documentation Page				Form Approved OMB No. 0704-0188	
Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.					
1. REPORT DATE 01 SEP 2014		2. REPORT TYPE N/A		3. DATES COVERED -	
4. TITLE AND SUBTITLE Extracorporeal blood purification in burns: A review				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Linden K., Stewart I. J., Kreyer S. F. X., Scaravilli V., Cannon J. W., Cancio L. C., Batchinsky A. I., Chung K. K.,				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) United States Army Institute of Surgical Research, JBSA Fort Sam Houston, TX				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 8	19a. NAME OF RESPONSIBLE PERSON
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified			

5.2. High cutoff membranes	1074
5.3. Coupled plasma filtration adsorption	1076
6. Selective Cytopheretic Device (SCD)	1076
7. Conclusion	1076
Acknowledgements	1076
References	1076

1. Introduction

Immune modulation by extracorporeal blood purification has been studied as a potential treatment for a variety of acute inflammatory states such as sepsis, pancreatitis, and after cardiac arrest [1,2]. Extracorporeal techniques have also been suggested to improve outcomes in patients with burns in the setting of organ dysfunction and refractory burn shock [3,4]. The purpose of this manuscript is to describe the scientific rationale behind extracorporeal blood purification, review the literature as this concept applies to the management of burn patients and review promising extracorporeal therapies.

2. Rationale for blood purification

There is a large body of evidence with respect to the inflammatory state associated with sepsis in critically ill patients [5]. This understanding may be applicable to the burn population because the genomic response in humans to inflammatory diseases is highly correlated, irrespective to the source of the insult [6]. The human response may represent a “final common pathway” that can be manipulated regardless of the source of inflammation. Therefore, our current understanding of sepsis should provide some insight into the processes related to the inflammatory state seen in burn patients. Sepsis is associated with a systemic inflammatory response syndrome (SIRS) which occurs due to increased expression of pro and anti inflammatory mediators [5,7,8]. In the early phase of SIRS, pro inflammatory cytokines predominate [5]. This is followed by a phase of high expression of anti inflammatory cytokines sometimes referred to as compensatory anti inflammatory response syndrome (CARS), which leads to immunosuppression [5,9]. It is hypothesized that this “cytokine storm” results in multiple organ dysfunction (MOD) and subsequent mortality. On the other hand, depressed or impaired cytokine production has also been seen in severe sepsis with high mortality [5]. A balanced level of inflammatory mediators seems to be necessary to survive sepsis. Based on this understanding, agents targeted to specific cytokines and key mediators have been examined in clinical trials. Interleukin 1 (IL 1) receptor antagonists, antibradykinin agents, anti tumor necrosis factor (TNF) antibodies, toll like receptor blockers and platelet activating factor receptor antagonists have been studied, but none have demonstrated a survival benefit in phase III trials [5,10,11]. Recombinant human activated protein C was the only agent to make it to market; however, it was subsequently withdrawn due to unfavorable post marketing data and lack of benefit in follow on studies [12]. A plausible hypothesis for the inability of specific targeted therapies to improve clinical outcomes is the relative complexity and redundancy of the

human body, with different cytokine profiles and host pathogen interactions [13] as well as the considerable variability in responses to a severe insult. The above factors make detailed understanding and selection of therapeutics problematic. Thus, a non selective approach via extracorporeal blood purification is an attractive treatment option while the pathophysiology of the inflammatory response is elucidated. Three hypotheses exist about the possible regulation of cytokine levels. The first one, the so called “peak concentration hypothesis,” states that by reducing total cytokine levels in the early pro inflammatory phase, subsequent MOD and mortality may be prevented. In contrast, the second one, called “threshold immunomodulation theory,” has a dynamic view of the different compartments. By non selectively removing cytokines from the blood, cytokines from the interstitium and tissues will also be reduced because they will follow the concentration gradient until a new equilibrium is achieved. At this point, the cascade of overwhelming inflammation should stop and organ damage could be prevented. Additionally, efficiency of mediator clearance is highly dependent on the concentration of the mediator. As such, mediators that are present at higher concentrations are likely to be cleared more effectively. In the third hypothesis, the “mediator delivery hypothesis,” the use of high replacement volumes may increase lymphatic flow, which helps to transport and deliver cytokines to the blood compartment where they can be removed using blood purification techniques [7,14]. Non selective blood purification does not target a specific mediator but removes cytokines based on their blood concentrations. By this approach, it is thought that abundant cytokines can be removed and a balanced state can be achieved. Still, we do not know all the components and regulation mechanisms of this complex system. One must be wary of possible unforeseen effects when modulating the inflammatory response in the face of these unknowns.

3. Pathophysiology of burns and why blood purification makes sense

Cytokines are elevated early in the course of burn injury without signs of sepsis [15–17]. Finnerty et al. examined the cytokine profile of children and adults after burn. This group found a greater inflammatory response in adults, compared to children, with high levels of IL 6, IL 8, IL 10, IL 4, IL 17, granulocyte macrophage colony stimulating factor (GM-CSF) and interferon gamma (INF- γ). IL 6, IL 8, IL 1 β , IL 18 and IL 10 showed the highest elevations during the first week after the burn injury [18,19]. Enhanced catabolism and metabolism, which have an important impact on prolonged morbidity and mortality, are associated with high levels of pro inflammatory cytokines in burns [15,20]. The inflammatory and hypermetabolic response has been shown to begin early, within the first 24 h after the

injury, and increases quickly over the first five days [15,21]. Of note is that in addition to proinflammatory cytokines, anti-inflammatory cytokines are also elevated. This inflammatory state early after burn injury, termed “cytokine storm” by some authors, is understood as disturbed cytokine homeostasis [8,14]. Every additional insult on top of this early inflammatory state, such as infections, sepsis and surgery, exacerbates the risk factor of MOD, which is associated with a very high mortality [22].

Rhabdomyolysis has been associated with both acute kidney injury (AKI) and mortality in the setting of burn injury [23–25].

Myoglobin, which is released from skeletal muscle after injury, is thought to contribute to the development of AKI by increasing oxygen free radical production and by precipitating with Tamm Horsfall protein in the renal tubule [26]. Early elimination of myoglobin by certain types of extracorporeal membranes might decrease the risk of renal failure and presumably subsequent MOD and death.

In summary, attempts to modulate inflammatory reactions, regulate cytokine homeostasis, and decrease myoglobin by blood purification in the early state of burn trauma seems to be a promising therapeutic option.

4. Blood purification techniques in burns

4.1. Plasma exchange

Plasma exchange or plasmapheresis has been studied as a rescue therapy in burn patients failing to respond to conventional fluid resuscitation. Despite the paucity of data, plasma exchange has been advocated as a strategy in severe or refractory burn shock at selected burn centers. Small studies in this population have demonstrated a decrease in the resuscitative fluid requirement, increase in mean arterial blood pressure, increase in urine output, decrease in lactate levels, improvement of lymphocyte function, and decrease of the mixed lymphocytic reaction [27,28]. No increase in adverse events was reported in these studies. To date, there are no studies that evaluate cytokine levels during plasma exchange in burn patients. Plasma exchange has also been studied in the context of sepsis. Similar to work in the burn population, small studies have shown improved hemodynamics, but a mortality benefit has yet to be determined [29,30]. Limitations of this technique must also be considered. In plasma exchange, the entire plasma volume is removed and replaced. This results in the removal not only of pathogenic factors (e.g., cytokines) but also of beneficial factors such as coagulation factors, immunoglobulins, and other plasma proteins. By removing such components, one might actually impair an adequate physiologic response. Moreover, it is not possible to regulate the amount of each substance that is removed, harmful or beneficial, using this technique. Furthermore, plasma exchange requires replacement with fresh frozen plasma and/or albumin. Transfusion of these human derived components carries the risk of infection, anaphylactic reactions, and transfusion related acute lung injury [31]. In conclusion, plasma exchange seems to be a potential therapeutic option in severe refractory burn shock, albeit one without a proven mortality benefit. Large, clinical trials are needed to determine

whether plasma exchange can improve outcomes in patients with burns and sepsis.

4.2. Continuous venovenous hemofiltration (CVVH)

CVVH is an accepted therapy in the setting of AKI. While traditional renal replacement therapies such as hemodialysis achieve clearance by means of the diffusion of solute across a semi permeable membrane, CVVH achieves clearance by means of convection (or ‘solute drag’). This is presumed to enhance the removal of water soluble middle molecular weight molecules (5–50 kDa) such as cytokines [1]. Clinical studies examining the use of CVVH as a therapy in septic patients demonstrate different results. Heering et al. showed improved hemodynamics and, while TNF α was detected in the ultrafiltrate, plasma levels of cytokines did not change [32]. A multicenter randomized trial using CVVH in septic patients and comparing it to a conventionally treated group of septic patients found a higher rate and severity of organ failure and no reduction of cytokine plasma levels [33]. It has been postulated that CVVH with high doses, so called high volume hemofiltration (HVHF), can lead to better results because of a higher effect of convection with enhanced removal of inflammatory mediators. In the recently published multicenter IVOIRE trial, patients with septic shock and AKI were randomized to either HVHF at 70 ml/kg/h or standard volume CVVH at 35 ml/kg/h [34]. No difference in 28 day mortality, hemodynamic profile, or organ function was demonstrated between the two groups. The authors came to the conclusion that HVHF cannot be recommended for treatment of septic shock complicated by AKI. It is important to note, however, that the study was stopped prior to the enrollment of the desired number of patients. This resulted in a low power that was insufficient to detect more subtle differences between the treatment groups [34]. Given the results of two other, large randomized controlled trials, the current recommendation is that renal replacement therapy should be prescribed at a rate of 25 ml/kg/h in patients with AKI [35,36]. There are less data regarding burn patients specifically. Our group examined, in a retrospective fashion, the early use of CVVH in severely burned patients with a total burn surface area (TBSA) >40% and AKI (as defined by the AKI Network criteria ≥ 2 [37]) [3]. The study included 29 patients treated with CVVH (doses ranged from 30 to 120 ml/kg/h) compared to a historical control group. The early use of CVVH was associated with a lower 28 day mortality and in hospital mortality compared to controls. Moreover, in patients with acute respiratory distress syndrome (ARDS), an improved ratio of partial pressure of oxygen (PaO₂) to the fraction of inspired oxygen (FiO₂) at 24 h in the CVVH group was observed. Significantly fewer patients required catecholamines at 24 and 48 h after CVVH initiation. While cytokines were not measured, the authors hypothesized that reduction of inflammatory mediators and resulting immunomodulatory effects might explain the results.

It is possible that different patient populations, severity of illness and types of organ failure might explain the differing results seen in the studies done to date. However, it is important to note that the two largest, randomized controlled trials failed to demonstrate an improvement in outcomes with a higher dose [35,36]. This implies that findings based on smaller groups are either due to type one error or that

improvements in surrogate measures (e.g., FiO_2 in patients with ARDS) are not clinically meaningful. However, the role of HVHF has not been thoroughly examined in burn patients specifically. The “Randomized controlled evaluation of hemo filtration in adult burn patients with septic shock and acute renal failure” (RESCUE) trial (NCT01213914) is ongoing and will address the potential utility of HVHF in the setting of burn injury. Patients in this study are randomized to treatment with HVHF at 70 ml/kg/h versus the standard care (which can include CVVH if it is dosed at <35 ml/kg/h). The primary outcome measure is total vasopressor requirement at the end of the 48 h therapy. Secondary outcome measures are $\text{PaO}_2/\text{FiO}_2$ ratio, vasopressor free days, survival time, days in the intensive care unit (ICU), ventilator free days, and renal recovery.

5. Emerging blood purification techniques

5.1. Adsorptive membranes and columns

The principle of adsorption is the binding of molecules (e.g., mediators, cytokines, antibiotics, and proteins) to a membrane or adsorptive column on the basis of ionic charge or size. Adsorptive membranes and columns have been designed to remove cytokines in the setting of SIRS and sepsis. Some of the technologies presented below (polymethylmethacrylate and high cut off membranes) are integrated into the membrane used for renal replacement therapy. Others (such as polymyxin B and CytoSorb[®]) are hemoperfusion columns that can be used in conjunction with renal replacement therapy (in series with either CVVH or conventional hemodialysis) and could also be used as stand alone systems. These novel extracorporeal therapies, targeted at non specific cytokine removal, could conceivably improve outcomes in the setting of burn injury.

5.1.1. Polymyxin B columns

Membranes bound with the antibiotic polymyxin B have the ability to bind endotoxin. In the Early Use of Polymyxin B Hemoperfusion in Abdominal Sepsis (EUPHAS) study [38], hemoperfusion with a polymyxin B column was evaluated in patients with sepsis due to intra abdominal infection. Hemoperfusion with the polymyxin B column improved hemodynamics, decreased organ dysfunction, and reduced 28 day mortality compared to controls. In the ongoing EUPHRATES study (NCT01046669), the use of a polymyxin B column in patients with septic shock and endotoxemia will be examined. The primary outcome measure is 28 day mortality, while secondary outcomes include 90 day, 6 month, and 12 month mortality.

While the specific pathogens may differ between centers, Gram negative organisms are the leading cause of life threatening infections in the setting of burn injury [39,40]. Therefore, polymyxin B columns could be a therapeutic option in burn patients with endotoxemia. Peng et al. studied the effect of CVVHD with polymyxin B immobilized fibers in septic burn patients (TBSA $\geq 50\%$) [41]. Plasma levels of endotoxin, IL 1 β , IL 6, IL 8 and TNF α were significantly decreased by this therapy. Outcomes could not be assessed given the small number of patients involved.

5.1.2. PMMA membranes

Polymethylmethacrylate (PMMA) membranes have been shown to be able to remove cytokines effectively [42], and clinical studies have shown an improvement in hemodynamics [2,43]. Regarding burn patients, Nakae et al. [44] reported on three cases with severe burn injury (TBSA >30%) treated with CVVH utilizing a PMMA membrane and found reduction in IL 6 levels in all three patients. Matsuda et al. compared the use of continuous hemodiafiltration with PMMA membrane vs. intermittent hemodialysis in patients with ARDS and renal failure [45]. They found a higher 28 day cumulative survival rate in the PMMA group. The PMMA membrane also resulted in a significant reduction in IL 6 levels.

5.1.3. Cytokine-adsorbing columns

Cytokine adsorbing columns are designed expressly for the non selective removal of cytokines [2,46]. They are composed of beads designed to capture and adsorb cytokines by size exclusion chromatography and nonselective hydrophobic interactions. Small molecules, below 10 kDa, travel through the pores of the beads while larger molecules and cells, above 50 kDa, pass around the beads. These columns have demonstrated the ability to reduce cytokines in vitro and improve mortality in animal models [47–50].

The column CytoSorb[®] has been tested in a multicenter randomized controlled study including 43 patients with sepsis and acute lung injury. Results of this study were presented recently [51]. Use of the cytokine adsorbing column significantly reduced IL 6, MCP 1, IL 1ra, and IL 8 levels. IL 10 and endotoxin do not seem to be removed in patients by CytoSorb[®]. While mortality did not differ between the two groups, the study was not powered for this endpoint. The CytoSorb[®] filter has also been demonstrated to efficiently remove myoglobin in vitro [52] and is a promising therapy for rhabdomyolysis that occurs in conjunction with thermal injury. A study of this technology in the setting of cardiopulmonary bypass is ongoing (NCT NCT01879176) and a study in trauma and burn patients with rhabdomyolysis is in the planning phase.

5.2. High-cutoff membranes

High cutoff (HCO) membranes have an in vivo cutoff point of 50–60 kDa. Most manufacturers recommend the use of these membranes with hemodialysis, which would result in cytokine removal primarily by diffusion. A decrease in IL 6 concentrations in septic patients with AKI (RIFLE class failure [53]) has been observed [54] as well as removal of middle weight molecules such as β_2 microglobulin and cystatin C [55]. However, the preliminary results of the “High Cut Off Sepsis (HICOSS) study” did not show a difference in mortality, duration of ICU stay, or need for catecholamines using the HCO membrane SepteX[®] compared to conventional continuous venovenous hemodialysis in patients with septic shock and AKI [2]. While use of these membranes in hemofiltration mode can increase albumin losses, some authors propose the use of HCO membranes with hemofiltration to improve cytokine removal by means of convective clearance [2,56]. A reduction of norepinephrine dose and a high clearance for IL 6 was shown in a pilot study using a HCO membrane in

Table 1 – Examples, technical details, and studies for a selection of membranes designed for cytokine removal.

Name	SepteX [®] Gambro	oXiris [®] Gambro	PMMA different Toray membranes	Polymyxin B Toraymyxin [®] , Toray	CytoSorb [®] CytoSorbents	CPFA [®] Bellco
Type	High cutoff membrane	Adsorptive membrane	Adsorptive membrane	Adsorptive membrane	Adsorbing column	Coupled plasma filtration and adsorption
Use	As CRRT in sepsis manufacturer recommends CVVHD; study planned in CVVH	As CRRT in sepsis Use in CVVH or CVVHDF modes	As CRRT In different modes	Sepsis/endotoxemia hemoperfusion	Cytokine hemoperfusion	In multi organ failure and/or sepsis CPFA
Fibers	Polyarylether sulfon	Acrylonitril + sodium methallyl sulfonate copolymer + polyethylenimine	Polymethylmethacrylate	Polymyxin B covalently immobilized; polystyrene derived	Cross linked divinylbenzene/polyvinylpyrrolidone beads	Reverse phase styrenic polymer resin
Surface	1.1 m ²	1.5 m ²	1 2.1 m ²	N/A	850 m ² /g	600 800 m ² /g
Studies/reviews in burn patients	N/A	N/A	Case report [44] reduction of IL 6	Reduction of endotoxin, IL 1 β , IL 6, IL 8, and TNF α ; no different outcomes compared to no treatment [41]	N/A Might be able to remove myoglobin	N/A
Studies/reviews in septic patients	Might play a role in removing myoglobin [2,23] Greater relative decrease of IL 6 than with high flux membrane [54] Preliminary results of HICOSS no difference in mortality, duration of ICU stay, need of catecholamines compared to conventional CVVHD membrane [2]	No studies in humans	Removed cytokines effectively and improved hemodynamics (CHDF mode) [43]	EUPHAS: improved hemodynamics, organ dysfunction, 28 day mortality in intra abdominal Gram negative infections [38]	CytoSorb's European Sepsis Trial: reduction in IL 6, MCP 1, IL 1ra and IL 8. No IL 10, 28 day, and 60 day mortality reduction. No removal of endotoxin [51]	Improved hemodynamics (CPFA + HD) compared to CVVHDF; may restore leukocyte responsiveness [58]

hemofiltration mode [57]. A study of 76 patients with shock and AKI (Study Comparing High Cut off Haemofiltration With Standard Haemofiltration in Acute Renal Failure, NCT00912184) has been completed but is yet to be published. Regarding burn patients, HCO membranes are seen as a possible important therapy in rhabdomyolysis [2,23].

5.3. Coupled plasma filtration adsorption

In coupled plasma filtration adsorption (CPFA), plasma is separated from the whole blood by a plasmafilter, and only the plasma is passed through the adsorption cartridge. The treated plasma is then returned and the whole blood passes a hemofilter or hemodialyser. Performing adsorption only on plasma might decrease platelet aggregation and clotting problems, thus allowing a longer contact time to the adsorbent with lower flows [1]. In one study of septic patients, CPFA with hemodialysis led to improved hemodynamics compared to CVVHDF and it was postulated that it restored leukocyte responsiveness [58]. Plasma levels of cytokines, however, were not reduced. A study of 350 patients with septic shock (COMPACT 2, NCT01639664) is ongoing and is expected to complete enrollment in 2016. There are no studies in burn patients regarding CPFA.

Table 1 gives an overview of adsorptive membranes and columns.

6. Selective Cytopheretic Device (SCD)

The Selective Cytopheretic Device (SCD) is another emerging technique of immunomodulation to alter excessive acute inflammatory response. It targets activated leucocytes, which are major contributors to the inflammatory response as they produce inflammatory mediators and have phagocytotic activity. The SCD is a cartridge containing bundled polysulfone fibers. Blood passes around these fibers at a low velocity, and the circuit is designed in such a way that shear forces are low. Leukocytes adhere to the surface. Citrate anticoagulation is required for this technique, which results in a low ionized calcium environment that causes subsequent deactivation of leukocytes. It is thought that this modulates the SIRS response [59–61]. This device has been used in two pilot studies in patients with AKI secondary to acute tubular necrosis with the cartridge connected in series to a CRRT circuit. One study of 9 patients revealed a mortality of 22.2% compared to a case matches historical control group mortality of 77.8% [60]. Another study of 35 patients showed a mortality of 31.4% and renal recovery in all surviving patients at day 60, compared to historical mortality rates of >50% for patients with AKI who require renal replacement therapy in the ICU [61]. A larger trial, the “Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients with Acute Kidney Injury” (NCT01400893), is ongoing, with an estimated enrollment of 344 patients.

7. Conclusion

Blood purification in burns for non specific removal of inflammatory mediators seems most likely to be effective in

the early stages after injury. Based on our current understanding of sepsis and the dysregulated inflammatory response, this might lead to improvements in morbidity and mortality. Adsorbing membranes and columns like PMMA and cytokine adsorbing columns seem to be particularly promising in the early stage of burn injury without AKI, whereas polymyxin B has a special ability to remove endotoxin in the setting of Gram negative infection. The SCD has so far been used only in patients with AKI, but they could offer immunomodulation in burn patients as well.

We believe that extra corporeal blood purification has the potential to revolutionize treatment for a variety of critically ill patients, including those with thermal injury. However, further investigations in both animal models and human clinical studies (including large prospective studies) are required to further elucidate the role of these therapies.

Conflict of interest statement

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army, Department of the Air Force or the Department of Defense. KL, IJS and AIB received funding to test the CytoSorb in animals as part of the SBIR phase II study awarded to CytoSorbents Corporation, Monmouth Junction, NJ. IJS and KKC received an Air Force grant (AFMSA/SG9 Grant, EM I 12 015) to evaluate Cytosorb in the treatment of rhabdomyolysis. KC is the principal investigator for the RESCUE trial (NCT01213914).

Acknowledgments

We thank Otilia Sánchez for her medical editing and formatting of this article.

This research was supported in part by an appointment to the Postgraduate Research Participation Program at the U.S. Army Institute of Surgical Research (USAISR) administered by Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and USAMRMC.

REFERENCES

- [1] Rimmelé T, Kellum JA. Clinical review: blood purification for sepsis. *Crit Care* 2011;15:205.
- [2] Honore PM, Jacobs R, Joannes Boyau O, De Regt J, De Waele E, van Gorp V, et al. Newly designed CRRT membranes for sepsis and SIRS – a pragmatic approach for bedside intensivists summarizing the more recent advances. *ASAIO J* 2013;59:99–106.
- [3] Chung KK, Lundy JB, Matson JR, Renz EM, White CE, King BT, et al. Continuous venovenous hemofiltration in severely burned patients with acute kidney injury: a cohort study. *Crit Care* 2009;13:R62.
- [4] Mosier MJ, Dechristopher PJ, Gamelli RL. Use of therapeutic plasma exchange in the burn unit: a review of the literature. *J Burn Care Res* 2013.

- [5] Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. *Lancet Infect Dis* 2013;13:260–8.
- [6] Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. *PNAS* 2013;110:600–6.
- [7] Honore PM, Jacobs R, Joannes Boyau O, Boer W, De Waele E, Van Gorp V, et al. Moving from a cytotoxic to a cytokinetic approach in the blood purification labyrinth: have we finally found ariadne's thread? *Mol Med* 2012;18:1363–5.
- [8] Namas R a, Namas R, Lagoa C, Barclay D, Mi Q, Zamora R, et al. Hemoadsorption reprograms inflammation in experimental Gram negative septic peritonitis: insights from in vivo and in silico studies. *Mol Med* 2012;18:1366–74.
- [9] Wiersinga WJ. Current insights in sepsis: from pathogenesis to new treatment targets. *Curr Opin Crit Care* 2011;17:480–6.
- [10] Deans KJ, Haley M, Natanson C, Eichacker PQ, Minneci PC. Novel therapies for sepsis: a review. *J Trauma Inj Infect Crit Care* 2005;58:867–74.
- [11] Wenzel RP, Edmond MB. Septic shock – evaluating another failed treatment. *N Engl J Med* 2012;366:2122–4.
- [12] Ranieri VM, Thompson BT, Barie PS, Dhainaut J F, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. *N Engl J Med* 2012;366:2055–64.
- [13] Angus DC. The search for effective therapy for sepsis: back to the drawing board? *JAMA* 2011;306:2614–5.
- [14] Honore PM, Joannes Boyau O, Boer W, Collin V. High volume hemofiltration in sepsis and SIRS: current concepts and future prospects. *Blood Purif* 2009;28:1–11.
- [15] Jeschke MG, Chinkes DL, Finnerty CC, Kulp G, Suman OE, Norbury WB, et al. Pathophysiologic response to severe burn injury. *Ann Surg* 2008;248:387–401.
- [16] Yamada Y, Endo S, Inada K. Plasma cytokine levels in patients with severe burn injury – with reference to the relationship between infection and prognosis. *Burns* 1996;22:587–93.
- [17] Yeh F, Lin W, Shen H, Fang R. Changes in circulating levels of interleukin 6 in burned patients. *Burns* 1999;25:131–6.
- [18] Finnerty CC, Herndon DN, Przkora R, Pereira CT, Oliveira HM, Queiroz DMM, et al. Cytokine expression profile over time in severely burned pediatric patients. *Shock* 2006;26:13–9.
- [19] Finnerty CC, Jeschke MG, Herndon DN, Gamelli R, Gibran N, Klein M, et al. Temporal cytokine profiles in severely burned patients: a comparison of adults and children. *Mol Med* 2008;14:553–60.
- [20] Jeschke MG, Mlcak RP, Finnerty CC, Norbury WB, Gauglitz GG, Kulp G a, et al. Burn size determines the inflammatory and hypermetabolic response. *Crit Care* 2007;11:R90.
- [21] Herndon DN, Tompkins RG. Support of the metabolic response to burn injury. *Lancet* 2004;363:1895–902.
- [22] Fitzwater J, Purdue GF, Hunt JL, O'Keefe GE. The risk factors and time course of sepsis and organ dysfunction after burn trauma. *J Trauma* 2003;54:959–66.
- [23] Stollwerck PL, Namdar T, Stang FH, Lange T, Mailänder P, Siemers F. Rhabdomyolysis and acute renal failure in severely burned patients. *Burns* 2011;37:240–8.
- [24] Mustonen K M, Vuola J. Acute renal failure in intensive care burn patients (ARF in burn patients). *J Burn Care Res* 2008;29:227–37.
- [25] Stewart IJ, Cotant CL, Tilley M a, Huzar TF, Aden JK, Snow BD, et al. Association of rhabdomyolysis with renal outcomes and mortality in burn patients. *J Burn Care Res* 2012;1–8.
- [26] Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. *N Engl J Med* 2009;361:62–72.
- [27] Neff LP, Allman JM, Holmes JH. The use of therapeutic plasma exchange (TPE) in the setting of refractory burn shock. *Burns* 2010;36:372–8.
- [28] Klein MB, Edwards F a, Kramer CB, Nester T, Heimbach DM, Gibran NS. The beneficial effects of plasma exchange after severe burn injury. *J Burn Care Res* 2005;30:243–8.
- [29] Venkataraman R, Subramanian S, Kellum JA. Clinical review: extracorporeal blood purification in severe sepsis. *Crit Care* 2003;7:139–45.
- [30] Reeves JH. A review of plasma exchange in sepsis. *Blood Purif* 2002;20:282–8.
- [31] Pandey S, Vyas GN. Adverse effects of plasma transfusion. *Transfusion* 2012;52(Suppl 1):65S–79S.
- [32] Heering P, Morgera S, Schmitz FJ, Schmitz G, Willers R, Schultheiss HP, et al. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. *Intensive Care Med* 1997;23:288–96.
- [33] Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaute E. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. *Crit Care Med* 2009;37:803–10.
- [34] Joannes Boyau O, Honoré PM, Perez P, Bagshaw SM, Grand H, Canivet J L, et al. High volume versus standard volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. *Intensive Care Med* 2013;39:1535–46.
- [35] Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D, et al. Intensity of renal support in critically ill patients with acute kidney injury. *N Engl J Med* 2008;359:7–20.
- [36] Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, et al. Intensity of continuous renal replacement therapy in critically ill patients. *N Engl J Med* 2009;361:1627–38.
- [37] Mehta RL, Kellum F a, Shah S V, Molitoris B a, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 2007;11:R31.
- [38] Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. *JAMA* 2009;301:2445–52.
- [39] Branski LK, Al Mousawi A, Rivero H, Jeschke MG, Sanford AP, Herndon DN. Emerging infections in burns. *Surg Infect (Larchmt)* 2009;10:389–97.
- [40] Keen EF, Robinson BJ, Hospenthal DR, Aldous WK, Wolf SE, Chung KK, et al. Prevalence of multidrug resistant organisms recovered at a military burn center. *Burns* 2010;36:819–25.
- [41] Peng Y, Yuan Z, Li H. Removal of inflammatory cytokines and endotoxin by veno venous continuous renal replacement therapy for burned patients with sepsis. *Burns* 2005;31:623–8.
- [42] Nakada T, Hirasawa H, Oda S, Shiga H, Matsuda K. Blood purification for hypercytokinemia. *Transfus Apher Sci* 2006;35:253–64.
- [43] Nakada T A, Oda S, Matsuda K I, Sadahiro T, Nakamura M, Abe R, et al. Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock. *Mol Med* 2000;14:257–63.
- [44] Nakae H, Motoyama S, Kurosawa S, Inaba H. The effective removal of proinflammatory cytokines by continuous hemofiltration with a polymethylmethacrylate membrane following severe burn injury: report of three cases. *Surg Today* 1999;29:762–5.
- [45] Matsuda K, Moriguchi T, Oda S, Hirasawa H. Efficacy of continuous hemodiafiltration with a cytokine adsorbing hemofilter in the treatment of acute respiratory distress syndrome. *Contrib Nephrol* 2010;166:83–92.

- [46] Taniguchi T. Cytokine adsorbing columns. *Contrib Nephrol* 2010;166:134–41.
- [47] Peng Z Y, Carter MJ, Kellum JA. Effects of hemoadsorption on cytokine removal and short term survival in septic rats. *Crit Care Med* 2008;36:1573–7.
- [48] Kellum F a, Song M, Venkataraman R. Hemoadsorption removes tumor necrosis factor, interleukin 6, and interleukin 10, reduces nuclear factor κ B DNA binding, and improves short term survival in lethal endotoxemia. *Crit Care Med* 2004;32:801–5.
- [49] Tsuda K, Taniguchi T. Effects of extracorporeal treatment with Lixelle on the mortality and inflammatory responses to endotoxin induced shock in rats. *Ther Apher Dial* 2006;10:49–53.
- [50] Taniguchi T, Kurita A, Yamamoto K, Inaba H. Comparison of a cytokine adsorbing column and an endotoxin absorbing column for the treatment of experimental endotoxemia. *Transfus Apher Sci* 2009;40:55–9.
- [51] Schädler D, Porzelius C, Jörres A, Marx G, Meier Hellmann A, Putensen C, et al. A multicenter randomized controlled study of an extracorporeal cytokine hemoadsorption device in septic patients. *Crit Care* 2013;17:P62.
- [52] Kuntsevich VI, Feinfeld D a, Audia PF, Young W, Capponi V, Markella M, et al. In vitro myoglobin clearance by a novel sorbent system. *Artif Cells Blood Substitutes Immobilization Biotechnol* 2009;37:45–7.
- [53] Bellomo R, Ronco C, Kellum a., Mehta RL, Palevsky P. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 2004;8:R204–12.
- [54] Haase M, Bellomo R, Baldwin I, Haase Fielitz A, Fealy N, Davenport P, et al. Hemodialysis membrane with a high molecular weight cutoff and cytokine levels in sepsis complicated by acute renal failure: a phase 1 randomized trial. *Am J Kidney Dis* 2007;50:296–304.
- [55] Schmidt JJ, Hafer C, Clajus C, Hadem J, Beutel G, Schmidt BMW, et al. New high cutoff dialyzer allows improved middle molecule clearance without an increase in albumin loss: a clinical crossover comparison in extended dialysis. *Blood Purif* 2012;34:246–52.
- [56] Morgera S, Klonower D, Rocktaschel J, Haase M, Priem F, Ziemer S, et al. TNF elimination with high cut off haemofilters: a feasible clinical modality for septic patients? *Nephrol Dial Transplant* 2003;18:1361–9.
- [57] Morgera S, Haase M, Kuss T, Vargas Hein O, Zuckermann Becker H, Melzer C, et al. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. *Crit Care Med* 2006;34:2099–104.
- [58] Ronco C, Brendolan A, Lonnemann G, Bellomo R, Piccinni P, Digito A, et al. A pilot study of coupled plasma filtration with adsorption in septic shock. *Crit Care Med* 2002;30:1250–5.
- [59] Humes HD, Sobota JT, Ding F, Song JH. A selective cytopheretic inhibitory device to treat the immunological dysregulation of acute and chronic renal failure. *Blood Purif* 2010;29:183–90.
- [60] Ding F, Yevzlin AS, Xu ZY, Zhou Y, Xie QH, Liu JF, et al. The effects of a novel therapeutic device on acute kidney injury outcomes in the intensive care unit: a pilot study. *ASAIO J* 2011;57:426–32.
- [61] Tumlin JA, Chawla L, Tolwani AJ, Mehta R, Dillon J, Finkel KW, et al. The effect of the selective cytopheretic device on acute kidney injury outcomes in the intensive care unit: a multicenter pilot study. *Semin Dial* 2013;26:616–23.